Why the study?
Does carvedilol improve left ventricular ejection fraction and alter renin-angiotensin system biomarkers in patients with chronic heart failure receiving ACE inhibitors?
Population
64 patients with chronic heart failure (CHF) receiving an ACE inhibitor
Comparison
Carvedilol for 6 months vs Matching placebo for 6 months
Design
RCT, randomized, double-blind, placebo-controlled
Follow-up
6 months
Authors
Loading...
Supports combining carvedilol with ACE inhibitors in chronic HF; extends mechanistic evidence for beta-blocker benefits on remodeling.
Does carvedilol improve left ventricular ejection fraction and alter renin-angiotensin system biomarkers in patients with chronic heart failure receiving ACE inhibitors?
In patients with chronic heart failure on ACE inhibitors, the addition of carvedilol over 6 months significantly improves LVEF and blunts active renin secretion, providing mechanistic insight into its clinical benefits.
Solal et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: